Featured News

01/13/2021

Chinese IPO Qilian Doubles in U.S. Trading Debut

Two Chinese initial public offerings opened for trading Tuesday, with Qilian International Holding Group making a powe...

02/24/2020

AnPac Bio-Medical Science Co., Ltd’s $16 Million Initial Public Offering

Cleary Gottlieb Steen & Hamilton LLP acted as counsel to the Company, and Sheppard Mullin Richter & Hampton LLP ...

11/15/2019

Chinese cancer diagnostics provider AnPac Bio-Medical Science sets terms for $22 million US IPO

AnPac Bio-Medical Science, a Chinese provider of multi-cancer screening tests, announced terms for its US IPO on Friday....

UNIVEST SECURITIES IN THE NEWS

10/31/2019

Univest Securities, LLC. Announces Closing of IPO for its Client Happiness Biotech Group Limited (NASDAQ: HAPP), Marking the Second Nasdaq IPO of Uinvest in 2019

New York, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Univest Securities, LLC, a FINRA and SIPC member full-service investment bank and securities broker-dealer firm, today announced the closing of previously announced the initial public offering (“IPO”) for its client Happiness Biotech Group Limited

10/25/2019

Traditional Chinese IPO: Happiness Biotech Group prices $11 million US IPO at $5.50

Happiness Biotech Group, a China-based provider of dietary supplements used in traditional Chinese medicine, raised $11 million by offering 2.0 million shares at $5.50, as filed. At the offer price, the company commands a market value of $138 million (LTM P/E of 7.9x).

10/25/2019

Happiness Biotech Group Limited Announces Pricing of US$11 Million Firm Commitment Initial Public Offering

NANPING, China, Oct. 25, 2019 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company"), an innovative China-based nutraceutical and dietary supplements producer, announced today the pricing of a U.S. underwritten initial public offering ("Offering") of 2,000,000 ordinary shares at a price to the public of $5.50 per share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on October 25, 2019 under the ticker symbol "HAPP."

04/11/2019

Spotlight: U.S.-China biotech cooperation benefits patients, investors in both countries

NEW YORK, April 10 (Xinhua) -- U.S.-China partnership in the biotech sector is promising and will benefit both patients and investors in the two countries, said U.S. biotech firms and investors.